IP Library Granted Patent US 10,045,997
Granted Patent B2
US 10,045,997 · App. 15/278,744 · Granted Aug 14, 2018

Hypotensive lipid and timolol compositions and methods of using same

Inventors: June Chen (San Juan Capistrano, CA); David F. Woodward (Lake Forest, CA); Alexander B. Kharlamb (Irvine, CA)
Assignee: ALLERGAN, INC.
A61K31/5575A61K9/0048A61K31/165A61K31/535A61K31/5377A61K31/557A61K45/06A61K47/02A61K47/12A61K47/186A61K47/10Y10S514/913
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,045,997
App. No.
15/278,744
Granted
Aug 14, 2018
Kind
B2
Abstract

New compositions for and methods of treating ocular hypertension provide for effective treatment of ocular hypertension often using reduced concentrations of active components. Such compositions include a timolol component and a hypotensive lipid component. The present compositions and methods are relatively straightforward, can be easily produced, for example, using conventional manufacturing techniques, and can be easily and conveniently practiced, for example, using application or administration techniques or methodologies which are substantially similar to those employed with prior compositions used to treat ocular hypertension.

Claims (4)

1. A method for treating ocular hypertension comprising topically administering to an eye in need thereof a first composition comprising a solution of about 0.68% (w/v) timolol maleate and about 0.03% (w/v) of cyclopentane N-ethyl heptenamide-5-cis-2-(3α-hydroxy-5-phenyl-1-trans-pentenyl)-3,5-dihydroxy, [1α,2β,3α,5α] in a single composition, wherein the first composition produces at least one reduced side effect relative to a second composition comprising a solution of 0.03% (w/v) cyclopentane N-ethyl heptenamide-5-cis-2-(3α-hydroxy-5-phenyl-1-trans-pentenyl)-3,5-dihydroxy, [1α,2β,3α,5α] without timolol.

2. The method of claim 1 , wherein the at least one reduced side effect is conjunctival hyperemia.

3. The method of claim 1 , wherein the first composition is applied once daily.

4. The method according to claim 1 or 2 , wherein the composition further comprises benzalkonium chloride.

Continuity (6)
Continuation 14535759 · Nov 7, 2014
Continuation 14062691 · Oct 24, 2013
Continuation 12408125 · Mar 20, 2009
Continuation 10153043 · May 22, 2002
Provisional Application 60294845 · May 31, 2001
Related Publication 20170112853A1 · Apr 27, 2017
Cited By (5)
US 12,226,422 US 12,419,933 US 12,496,326 US 12,569,452 US 12,599,607